home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday ↗

January 04, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗

January 04, 2023

Via Benzinga

Deciphera Pharmaceuticals's Return On Capital Employed Insights ↗

November 22, 2022

Via Benzinga

Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients ↗

January 04, 2023

Via Benzinga

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company

January 03, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

January 03, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Earns Price Target Bump With Encouraging ESMO Presentation ↗

September 12, 2022

Via Benzinga

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗

December 14, 2022

Via Benzinga

Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit

December 01, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

November 08, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results

November 03, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Earnings Outlook For Deciphera Pharmaceuticals ↗

November 02, 2022

Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

October 27, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Where Deciphera Pharmaceuticals Stands With Analysts ↗

September 27, 2022

Over the past 3 months, 7 analysts have published their opinion on Deciphera Pharmaceuticals (NASDAQ:DCPH) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

McDonald's Price Target Cut By This Analyst, Plus Cowen Predicts $362 For Domino's Pizza ↗

September 27, 2022

Citigroup cut McDonald's Corporation (NYSE: MCD) price target from $275 to $246. McDonald's shares rose 0.5% to $245.00 in pre-market trading.

Via Benzinga

SVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To Know ↗

September 12, 2022

SVB Leerink has decided to maintain its Outperform rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) and raise its price target from $21.00 to $25.00. Shares of Deciphera Pharmaceuticals are trading up...

Via Benzinga

This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe ↗

September 12, 2022

Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading.

Via Benzinga

Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday ↗

September 12, 2022

Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock....

Via Benzinga

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

September 11, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

September 10, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022

September 01, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

4 Analysts Have This to Say About Deciphera Pharmaceuticals ↗

August 29, 2022

Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗

August 29, 2022

Upgrades

Via Benzinga

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer ↗

August 11, 2022

Via Benzinga

Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology

August 10, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results

August 04, 2022

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com